A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
Public ClinicalTrials.gov record NCT04891965. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, placebo-controlled, double-blind, multi-site study in which up to approximately 36 subjects with a recent C. difficile infection (CDI) who have completed a standard of care course of CDI antibiotics and have achieved clinical cure based on signs and symptoms, will be randomized to 7 or 28 daily doses of ART24 or placebo. Subjects will be followed for 6 months after the last dose of study drug.
Study identification
- NCT ID
- NCT04891965
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2020 (Actual)
- Primary completion
- Jul 7, 2022 (Actual)
- Completion
- Oct 13, 2022 (Actual)
- Last update posted
- Oct 17, 2022
2020 – 2022
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palmtree Clinical Research | Palm Springs | California | 92262 | — |
| Gastro Florida | Clearwater | Florida | 33765 | — |
| Doral Medical Research | Doral | Florida | 33166 | — |
| Louisiana Research Center | Shreveport | Louisiana | 71105 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Mercury Street Medical Group | Butte | Montana | 59701 | — |
| DiGiovanna Institute | Massapequa | New York | 11758 | — |
| NYU Grossman School of Medicine | New York | New York | 10016 | — |
| Weill Cornell Medicine | New York | New York | 10021 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Frontier Clinical Research, LLC | Uniontown | Pennsylvania | 15401 | — |
| Advanced Clinical Research | Riverton | Utah | 84065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04891965, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2022 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04891965 live on ClinicalTrials.gov.